2024 Biosimilars Pharmaceutical Manufacturing 
Express Pharma
NOVEMBER 13, 2024
The 17th edition of CPHI & PMEC India, organised by Informa Markets in India, returns in an advanced format, scheduled from November 26-28, 2024, at the India Expo Centre, Greater Noida, Delhi-NCR. India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030.
Express Pharma
MARCH 16, 2025
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. and Europe. and Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
NOVEMBER 26, 2024
Integrating IT with pharmaceuticals will further strengthen its role, paving the way for dominance in biologics and biosimilars. The day concluded with the prestigious India Pharma Awards 2024, celebrating outstanding achievements in innovation and excellence within the pharmaceutical industry. With exports nearing $27.84
Big Molecule Watch
JANUARY 7, 2025
On Dec 24, 2024, Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, a proposed ustekinumab biosimilar to Jansen’s STELARA, in Saudi Arabia. Also on December 24, 2024, GlycoNex, Inc.
Drug Channels
JULY 23, 2024
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.
Express Pharma
NOVEMBER 18, 2024
The 17th edition of CPHI & PMEC India, organised by Informa Markets in India, will take place from 26th to 28th November 2024 at the India Expo Centre, Greater Noida, Delhi-NCR. The event will showcase developments in pharmaceutical modernisation, innovation, and sustainability.
FDA Law Blog: Biosimilars
JUNE 24, 2024
The event, titled “New and Improved – AMCP Format for Formulary Submissions v5.0,” aims to educate pharmaceutical manufacturers and other healthcare stakeholders on the latest updates and best practices in dossier development. released in April 2024, marks the first update since 2020. The latest iteration, version 5.0,
Expert insights. Personalized for you.
105 
Let's personalize your content